| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Anteris Technologies Global Corp.$10.57
+0.33 (+3.22%)
Market Cap
936.43 M
EPS
-2.22
P/E Ratio
-
Value Trade
9.59 M
SEC Financials
Q1 2026Dilution Risk
Revenue
494.00 K
R&D Expenses
17.46 M
Operating CF
-28.68 M
Total Assets
294.72 M
Total Liabilities
16.31 M
Equity
278.44 M
D/E Ratio
12,345
34.73 %
Week
65.58 %
1 Month
68.48 %
3 Month
185.46 %
6 Month
60.33 %
5 Year
60.33 %
All Time
Cash Data
Cash Position
283.21 M
Monthly Burn
9.56 M
Runway
27.9 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
2.35 M
52 Week Range
2.85 - 9.79
% held by Insiders
16.58 %
% held by Institutions
67.94 %
Enterprise Value
656.92 M
Total Shares
97.35 M
Short %
6.99 %
Float Shares
81.29 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
DurAVR THV | severe aortic stenosis | — | 2025-11-17 | single digit mean gradients; large effective orifice areas (EOAs); no moderate or severe paravalvular leaks; no valve related mortality; 97% freedom from moderate or severe prosthesis-patient mismatch Read More | Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves MINNEAPOLIS, United States and BRISBANE, Australia 17 November 2025: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASD Read More | |
DurAVR THV | severe aortic stenosis | — | 2025-11-17 | single digit mean gradients; large effective orifice areas (EOAs); no moderate or severe paravalvular leaks; no valve related mortality; 97% freedom from moderate or severe prosthesis-patient mismatch Read More | Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves MINNEAPOLIS, United States and BRISBANE, Australia 17 November 2025: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASD Read More | |
DurAVR THV | severe aortic stenosis | — | 2025-11-17 | single digit mean gradients; large effective orifice areas (EOAs); no moderate or severe paravalvular leaks; no valve related mortality; 97% freedom from moderate or severe prosthesis-patient mismatch Read More | Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves MINNEAPOLIS, United States and BRISBANE, Australia 17 November 2025: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASD Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AVR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AVR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AVRAnteris Advances Global PARADIGM Expansion with French Regulatory Clearance
Anteris Technologies Global Corp. has secured full regulatory clearance from the French National Agency for Medicines and Health Products Safety for its DurAVR Transcatheter Heart Valve in the PARADIGM clinical trial. This authorization enables the company to begin patient recruitment in France, marking a key milestone in its global clinical strategy. The trial aims to evaluate the safety and efficacy of the DurAVR valve compared to available transcatheter aortic valve replacements, with an enrollment goal of approximately 1,000 patients. Anteris is committed to advancing treatment options for severe calcific aortic stenosis.
Read more →AVRAnteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
Anteris Technologies has appointed Susan Knight and Stephen Denaro to its Board of Directors. Knight brings extensive experience from her previous roles, while Denaro returns with deep knowledge of the company. These appointments aim to strengthen governance and support the company's clinical and commercial objectives, particularly for the DurAVR® THV.
Read more →AVRAnteris Announces Results for the First Quarter of 2026
Anteris Technologies reported its Q1 2026 financial results, highlighting strong execution in the PARADIGM Trial with ongoing patient enrollment in Europe and the U.S. The company noted that recent CMS coverage will support recruitment efforts. However, they reported significant cash outflows due to clinical and regulatory expenses.
Read more →AVRAnteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial
Anteris Technologies has announced the successful enrollment and treatment of the first U.S. patients in its global pivotal PARADIGM Trial for the DurAVR® Transcatheter Heart Valve. This trial aims to evaluate the safety and effectiveness of their innovative heart valve compared to existing transcatheter aortic valve replacements. Dr. Azeem Latib has reported promising early experiences with the new valve, highlighting the trial's importance in advancing heart care. The study is aimed at enrolling approximately 1000 patients to assess various health outcomes over the course of the trial.
Read more →AVRAnteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial
Anteris Technologies has announced that it secured U.S. Medicare reimbursement eligibility for its PARADIGM Trial, which will evaluate the DurAVR® Transcatheter Heart Valve against commercially available TAVRs. This milestone is expected to enhance U.S. site activation and operational momentum. The trial aims to enroll around 1000 patients to assess the safety and effectiveness of the DurAVR® THV.
Read more →AVRAnteris Reports 2025 Financial Results and Provides Corporate Update
Anteris Technologies reported its 2025 financial results, highlighting advancements in its DurAVR product and the initiation of the PARADIGM Trial. The company aims to strengthen its position in the structural heart market while managing significant cash outflows related to clinical and regulatory needs. CEO Wayne Paterson emphasized the importance of clinical evidence and sustainable value creation.
Read more →AVRResults for announcement to the market Name of entity: Anteris Technologies Global Corp. ("ATGC") ARBN: 677 960 235 Reporting period: For the year ended 31 December 2025 The attached Form 10-K Annual Report for the year
Anteris Technologies Global Corp. has released its Form 10-K Annual Report for the year ended December 31, 2025. The report indicates a significant decline in revenue and an increase in net losses compared to the prior year. Despite the financial challenges, Anteris is notable for its innovative DurAVR Transcatheter Heart Valve, designed to address aortic stenosis. The company continues to report on its developments and financial maneuvers in compliance with respect to ASX listing rules.
Read more →AVRAnteris to Present at Healthcare Investor Conferences TD Cowen and Barclays
Anteris Technologies Global Corp. will present at the TD Cowen and Barclays Healthcare Conferences. CEO Wayne Paterson will discuss the company's innovative heart devices, including the DurAVR® Transcatheter Heart Valve, designed to treat aortic stenosis. The webcasts of the presentations will be available on the company's website.
Read more →AVRAnteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
Anteris Technologies Global Corp. has successfully closed a public offering of 40 million shares at $5.75 each, raising approximately $230 million. Additionally, the company completed a private placement of over 15 million shares to Medtronic, totaling around $320 million in gross proceeds. The funds will be used to advance their clinical strategy, particularly for the DurAVR® Transcatheter Heart Valve trial.
Read more →AVRAnteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
Anteris Technologies has secured a $90 million strategic investment from Medtronic, contributing to a total of $320 million raised. This funding will facilitate the global pivotal PARADIGM trial for the DurAVR® Transcatheter Heart Valve (THV). Both companies aim to enhance the TAVR market through innovation and improved patient outcomes.
Read more →AVRAnteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at $5.75 each, aiming to raise approximately $200 million. The offering is set to close on January 22, 2026, and will support the company's clinical strategy, including the DurAVR®THV global pivotal trial. Additionally, a private placement with Medtronic for up to $90 million is planned, contingent on the completion of the offering.
Read more →AVRAnteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic
Anteris Technologies Global Corp. has announced a proposed public offering of $200 million in common stock, with an additional $30 million option for underwriters. The company will also engage in a private placement with Medtronic for up to $90 million. Proceeds will support the DurAVR®THV global pivotal trial and expand manufacturing capabilities.
Read more →AVRAnteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves MINNEAPOLIS, United States and BRISBANE, Australia 17 November 2025: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASD
Anteris Technologies Global Corp. presented promising 30-day clinical outcomes from a cohort of 100 patients with severe aortic stenosis treated with the DurAVR THV valve at the PCR London Valves conference. The data revealed single-digit mean gradients and effective orifice areas, alongside no significant complications like valve-related mortality or paravalvular leaks. The results also indicated a remarkable 97% freedom from moderate or severe prosthesis-patient mismatch, offering optimism for the valve’s performance in small aortic annuli patients. The findings are expected to bolster confidence as the company progresses towards larger trials and commercialization efforts.
Read more →AVRResults for announcement to the market Name of entity: Anteris Technologies Global Corp. ("ATGC") ARBN: 677 960 235 Reporting period: For the quarter ended
Anteris Technologies Global Corp. (AVR) has filed its Form 10-Q for the quarter ending September 30, 2025, highlighting financial activities including an IPO that generated US$80 million in net proceeds. The report is essential for compliance with ASX regulations, and key business activities are also outlined. Their lead product, the DurAVR Transcatheter Heart Valve, is noted for its innovative design aimed at treating aortic stenosis. However, the report includes significant payments to related parties, which could raise governance issues.
Read more →AVRAnteris Announces Results for the Third Quarter of 2025
Anteris Technologies reported its financial results for Q3 2025, highlighting substantial progress in regulatory approvals for the PARADIGM Trial. The company received FDA approval to commence patient recruitment and secured initial European approvals. Operational readiness activities were completed, and the first patients were treated in Denmark. Anteris continues to strengthen its infrastructure to support upcoming clinical activities.
Read more →AVRFDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
Anteris Technologies has received FDA approval to initiate the PARADIGM Trial, a global clinical study evaluating the DurAVR® Transcatheter Heart Valve for patients with severe calcific aortic stenosis. The trial will compare the DurAVR® THV against existing TAVR devices, enrolling approximately 1000 patients across the U.S., Europe, and Canada. This trial is a crucial step toward securing Premarket Approval from the FDA.
Read more →AVRAnteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year
Anteris Technologies announced positive one-year clinical outcomes for its DurAVR® Transcatheter Heart Valve (THV) in patients with small aortic annuli. The valve showed impressive hemodynamic performance, with no valve-related mortality and low prosthesis-patient mismatch. These results will be further validated in the upcoming PARADIGM Trial, aimed at comparing DurAVR® THV with existing TAVR options.
Read more →AVRAnteris Technologies Announces First Patients Treated in DurAVR THV Global Pivotal Trial (the "PARADIGM Trial") MINNEAPOLIS, United States and BRISBANE, Australia 27 October 2025: Anteris Technologies Global Corp. ( Ante
Anteris Technologies has announced the successful enrollment and treatment of the first patients in the DurAVR Transcatheter Heart Valve (THV) global pivotal trial, known as the PARADIGM Trial, which is aimed at assessing treatment options for severe calcific aortic stenosis. This trial is a significant step towards advancing the DurAVR THV towards commercialization and is expected to generate the required clinical evidence for its effectiveness. The PARADIGM Trial will enroll approximately 1,000 patients and will provide comparative data against existing transcatheter aortic valve replacements. Anteris plans to expand the trial to additional regions including the United States, Europe, and Canada.
Read more →AVRAnteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025
Anteris Technologies announced that one-year clinical outcomes for its DurAVR® Transcatheter Heart Valve (THV) will be presented at TCT® 2025. The presentation will focus on outcomes in patients with small aortic annuli. The results from over 100 patients will be further evaluated in the upcoming PARADIGM Trial, which aims to compare DurAVR® THV with existing treatments.
Read more →AVROctober 2025 NASDAQ: AVR | ASX: AVR Disclaimer This presentation has been prepared by Anteris Technologies Global Corp. ("Anteris," the "Company," "we" or "us" or "our"). This presentation, and its contents and the accom
Anteris Technologies Global Corp. has prepared a presentation for stakeholders regarding its progress and strategy in the TAVR market. The company successfully completed its U.S. IPO and is building commercial readiness for its innovative DurAVR THV, which mimics a healthy aortic valve. They have reported positive momentum in patient enrollment for their treatments and aim to disrupt the underpenetrated market for severe aortic stenosis patients. Additionally, Anteris is set to launch the pivotal PARADIGM Trial, which is targeted for the fourth quarter of 2025.
Read more →AVRAnteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
Anteris Technologies has received regulatory clearance from the Danish Medicines Agency to initiate the global pivotal trial for its DurAVR® Transcatheter Heart Valve (THV) in patients with severe calcific aortic stenosis. The PARADIGM Trial aims to evaluate the safety and effectiveness of DurAVR compared to existing TAVR devices. Recruitment is set to begin in Denmark in Q4 2025, with plans for expansion into the U.S., Europe, and Canada.
Read more →AVRAnteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
Anteris Technologies Global Corp. has announced the adjournment of its Special Meeting of Stockholders originally scheduled for September 18, 2025, due to insufficient quorum. The meeting will now take place virtually on September 29, 2025, allowing stockholders more time to vote on proposals outlined in the Proxy Statement. The record date for voting remains unchanged.
Read more →AVRAnteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
Anteris Technologies Global Corp. has postponed its Special Meeting of Stockholders originally set for September 11, 2025. The meeting will now take place virtually on September 18, 2025, to allow more stockholders to participate and vote. The record date remains unchanged, and the Board encourages stockholders to vote in favor of the proposals outlined in the Proxy Statement.
Read more →AVRAnteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders MINNEAPOLIS and
Anteris Technologies Global Corp. has postponed its Special Meeting of Stockholders, originally scheduled for September 4, 2025, to September 11, 2025. The decision was made to provide stockholders with additional time to vote, thus facilitating broader participation. The meeting will now be held virtually, allowing stakeholders to attend via live webcast. Despite the change in date, the record date for voting remains unchanged.
Read more →AVRAnteris Announces Results for the Second Quarter of 2025
Anteris Technologies Global Corp. reported its financial results for the second quarter of 2025, highlighting progress in its DurAVR® THV implantations and preparations for the PARADIGM Trial. The company successfully treated 130 patients, including a world-first implant of two valves in a single patient. Preparations for the pivotal trial are advancing, with 79 clinical sites now qualified. Additionally, Anteris appointed two experienced executives to its Board to enhance leadership as it progresses clinically and commercially.
Read more →AVRWaiver from ASX Listing Rule 7.1 MINNEAPOLIS, United States and BRISBANE, Australia 7 August 2025: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) announces that ASX has granted the C
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) has received a waiver from ASX Listing Rule 7.1, allowing the company to issue new securities without needing approval from security holders. This exception is aimed at providing the company with more flexibility in financing and capital-raising activities. The waiver is important as it aligns Anteris with U.S. public companies that do not face similar restrictions. The board believes that this decision is in the best interests of the company and its shareholders.
Read more →AVRAnteris Appoints David Roberts and Gregory Moss to its Board of Directors
Anteris Technologies has announced the appointment of David Roberts and Gregory Moss to its Board of Directors, enhancing its leadership team as the company prepares for the pivotal PARADIGM trial for the DurAVR THV device. Roberts, a seasoned executive from LeMaitre Vascular, and Moss, who has significant legal and compliance experience, are expected to drive the company’s growth strategy. The board also acknowledged the contributions of outgoing director Dr. Wenyi Gu as he completes his tenure. These moves follow Anteris’ recent listing on NASDAQ, marking a significant phase in the company's development.
Read more →AVRASX Quarterly Results Announcement Name of entity: Anteris Technologies Global Corp. ("ATGC") ARBN: 677 960 235 Reporting period: For the quarter ended
Anteris Technologies Global Corp. reported their quarterly results for the period ending March 31, 2025, highlighting a successful IPO that generated net proceeds of US$80 million. The report includes compliance details and a financial overview consistent with US GAAP. Notably, the company's lead product, the DurAVR Transcatheter Heart Valve, aims to treat aortic stenosis and has been successfully utilized in a significant number of patients. The announcement also emphasizes forward-looking statements that outline the company's future objectives alongside associated risks.
Read more →AVRAnteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR THV MINNEAPOLIS, United States and BRISBANE, Australia 31 March 2025: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ
Anteris Technologies has announced a significant clinical milestone, having treated over 100 patients with its DurAVR Transcatheter Heart Valve (THV). This achievement highlights the device's potential to restore heart valve function and improve outcomes for patients with severe aortic stenosis. The company plans to commence the pivotal trial for DurAVR in the third quarter of 2025, pending FDA approval. Experts involved in the trial have expressed confidence in the clinical relevance of the device, which is considered a groundbreaking innovation in cardiac care.
Read more →AVRAnteris Reports One-Year Patient Outcomes for DurAVR THV New class, biomimetic TAVR demonstrates sustained hemodynamic performance to one-year MINNEAPOLIS, United States and BRISBANE, Australia 21 March 2025: Anteris Tec
Anteris Technologies Global Corp. reported encouraging one-year patient outcomes for its balloon expandable DurAVR Transcatheter Heart Valve (THV) System. The data indicates excellent effective orifice area and low mean gradients, with significant results, such as no prosthesis-patient mismatch in small annuli patients. The findings highlight the potential benefits of DurAVR in addressing long-term patient outcomes, reinforcing the company's plan for a pivotal trial following the Investigational Device Exemption submission to the U.S. FDA.
Read more →AVRResults Announcement Name of entity: Anteris Technologies Global Corp. ARBN: 677 960 235 Reporting period: For the year ended
Anteris Technologies Global Corp. has reported its financial results for the year ended December 31, 2024, showing a decrease in revenues and a substantial increase in losses. Revenues from ordinary activities slightly declined by 1%, while the loss after tax grew significantly by 62% compared to the previous year. The company's auditor expressed concerns regarding its ability to continue as a going concern, indicating potential financial instability. Additionally, there were no dividends proposed during this fiscal year.
Read more →AVRASX ANNOUNCEMENT 15 January 2025 Partial Exercise of Over-Allotment Option and End of Stabilisation Period Partial Exercise of the over-allotment option Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) ( Anteris
Anteris Technologies Global Corp. announced the partial exercise of the over-allotment option connected to its initial public offering which closed on December 16, 2024. The company confirmed that 78,481 shares were purchased at $6.00 each and that the remaining unexercised portion lapsed on January 11, 2025. Additionally, market stabilization activities have ceased as of January 12, 2025, marking the end of stabilization for its Common Stock. Anteris specializes in developing innovative medical devices aimed at restoring heart function.
Read more →Competitive Position
How AVR ranks across every disease it competes inCompetitive Position is a premium feature
See how AVR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial